| Literature DB >> 29153202 |
Alberto M Marra1, Emanuele Bobbio2, Roberta D'Assante1, Andrea Salzano3, Michele Arcopinto2, Eduardo Bossone4, Antonio Cittadini5.
Abstract
The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.Entities:
Keywords: Anabolic deficiency; Biomarker; Chronic heart failure; Growth hormone; IGF-1; Outcomes
Mesh:
Substances:
Year: 2018 PMID: 29153202 DOI: 10.1016/j.hfc.2017.08.008
Source DB: PubMed Journal: Heart Fail Clin ISSN: 1551-7136 Impact factor: 3.179